MYTHS AND FACTS OF BIOSIMILAR MONOCLONAL ANTIBODIES
With this article we intend to present facts and to expose several myths concerning the quality, safety and efficacy of therapeutic biosimilar monoclonal antibodies. We wish to summarize the experience of EMA regarding the biosimilar mAb and address the outstanding issues concerning the regulation a...
Saved in:
Main Author: | João Gonçalves (Author) |
---|---|
Format: | Book |
Published: |
Formifarma, LDA.,
2015-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
by: Evelien Moorkens, et al.
Published: (2020) -
Antidepressants: Myths, facts and perspectives
by: Obradović Aleksandar Lj, et al.
Published: (2017) -
Female Doctors: Myths and Facts
by: Bilal Bin Younis
Published: (2019) -
Journal indexing: Myths and facts
by: Ranjan Agrawal
Published: (2020) -
Creatine supplementation: facts and myths
by: Weronika Kawecka, et al.
Published: (2024)